SIENNA BIOPHARMACEUTICALS INC

As of September 30, 2019, SIENNA BIOPHARMACEUTICALS INC carries a market capitalization of 6.15M, placing it among publicly traded companies globally. Its enterprise value stands at -5.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2019, SIENNA BIOPHARMACEUTICALS INC has 30.77M shares outstanding.

These figures are as of September 30, 2019.

As of September 30, 2019, SIENNA BIOPHARMACEUTICALS INC maintains a current ratio of 15.27, meaning it holds 15.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2019, SIENNA BIOPHARMACEUTICALS INC posted a negative return on equity (ROE) of -140.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -57.04, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2019, SIENNA BIOPHARMACEUTICALS INC recorded an income tax benefit of -4.62M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -52.57M and -47.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, SIENNA BIOPHARMACEUTICALS INC's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended September 30, 2019, SIENNA BIOPHARMACEUTICALS INC generated - - in revenue and converted that into -47.95M in net income, yielding earnings per share of -1.80. EBITDA reached -49.22M, while operating income came in at -52.18M.

These figures are as of September 30, 2019. Total book value stands at 23.10M, with working capital of 18.44M providing operational flexibility.

SIENNA BIOPHARMACEUTICALS INC produced -54.63M in operating cash flow over the twelve months ended September 30, 2019. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -54.64M - equivalent to -2.05 per share.

These figures cover the twelve months ended September 30, 2019. Free cash flow yield is negative at -1,026.17: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.28, meaning SIENNA BIOPHARMACEUTICALS INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2019, SIENNA BIOPHARMACEUTICALS INC has an Altman Z-Score of -20.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.